Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 5/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6599858 | 1.00 | MEN1 (0.35) | MEN1KMT2AGAAHCAR2MAPT | |
| SCHEMBL29012774 | 0.80 | CTSK (0.41) | MEN1KMT2AGAATDP1CTSK | |
| SCHEMBL3926929 | 0.78 | TDP1 (0.36) | MEN1KMT2AGAATDP1CTSK | |
| SCHEMBL6599876 | 0.78 | HCAR2 (0.42) | MEN1KMT2AHCAR2MAPTTDP1 | |
| SCHEMBL6599872 | 0.78 | HCAR2 (0.42) | MEN1KMT2AHCAR2MAPTTDP1 | |
| SCHEMBL7649829 | 0.77 | CYP2D6 (0.37) | MEN1KMT2AGAAMAPTTDP1 | |
| SCHEMBL7649834 | 0.77 | CYP2D6 (0.37) | MEN1KMT2AGAAMAPTTDP1 | |
| SCHEMBL24061692 | 0.76 | CTSK (0.38) | MEN1KMT2AGAAMAPTTDP1 | |
| SCHEMBL293062 | 0.75 | CTSK (0.40) | MEN1KMT2AGAATDP1CTSK | |
| SCHEMBL24517966 | 0.74 | TDP1 (0.36) | MEN1KMT2AGAATDP1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172940-A1 | METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20220144826-A1 | Heteroaromatic and Heterobicyclic Aromatic Derivatives for the Treatment of Ferroptosis-Related Disorders | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2022-05-12 | — | — | US | disclosed |
| EP-3938340-A1 | HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS | Collaborative Medicinal Development, LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| WO-2020185738-A1 | HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2020-09-17 | — | — | WO | disclosed |
| EP-0805816-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2004-07-28 | — | — | EP | disclosed |
| US-6350767-B1 | GROWTH HORMONE RELEASE STIMULANT | NOVO NORDISK A/S (DK) | 2002-02-26 | — | — | US | disclosed |
| US-6013658-A | ANIMAL GROWTH REGULATORS | NOVO NORDISK A/S (DK) | 2000-01-11 | — | — | US | disclosed |
| EP-0805816-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022997-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172940-A1 | METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS | GPX4, GPX1, AIFM2 | MEN1 2820/4885KMT2A 3080/4885GAA 1480/4885 |
| US-20220144826-A1 | Heteroaromatic and Heterobicyclic Aromatic Derivatives for the Treatment of Ferroptosis-Related Disorders | AIFM2, FECH, SLC40A1 | MEN1 2006/4885KMT2A 2445/4885GAA 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.